Diagnostic accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: an overview of reviews

This overview of reviews examines the diagnostic test accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of prostate cancer.

Date of publication: 21 Jun 2024
Authors: Andrew Dullea, Lydia O'Sullivan, Marie Carrigan, Susan Ahern, Maeve McGarry, Kirsty O'Brien, Patricia Harrington, Kieran A. Walsh, Susan M. Smith, Máirín Ryan
Journal: Seminars in Nuclear Medicine
Digital object identifier: 10.1053/j.semnuclmed.2024.05.003
Type of output: Evidence synthesis
Suggested Citation:

Dullea A, O'Sullivan L, O'Brien KK, Carrigan M, Ahern S, McGarry M, et al. Diagnostic Accuracy of 18F-Prostate Specific Membrane Antigen (PSMA) PET/CT Radiotracers in Staging and Restaging of Patients With High-Risk Prostate Cancer or Biochemical Recurrence: An Overview of Reviews. Seminars in Nuclear Medicine. 2024. Available from: https://doi.org/10.1053/j.semnuclmed.2024.05.003

Generic justification

¹⁸F-prostate-specific membrane antigen (PSMA) PET/CT imaging for the staging of high-risk or recurrent prostate cancer: Evidence synthesis to support a generic justification decision

Published
Read publication